Saikosaponin-d (SsD), an FTO inhibitor, improved the efficacy of nilotinib and PKC412 by reducing FTO-mediated m6A hypomethylation and Bcl-2 transcripts in AML-resistant patients [137]. Here, FTO is linked to acute myeloid leukemia.